Truist reiterates Buy on Scholar Rock stock after Roche halts rival drug

Roche discontinued development of emugrobart after trials failed to show consistent muscle-growth and motor improvements in SMA and FSHD, a development that lifted Scholar Rock shares to $45.50 and strengthens Scholar Rock's competitive positioning. Truist reiterated a Buy with a $55 PT; multiple firms raised targets (Barclays $53, Piper $58, JPMorgan $50, BMO $70) and five analysts revised earnings higher (PT range $48–$70); Scholar Rock finished FY2025 with $367.6M cash and has access to up to $550M in debt financing to support the commercial launch of apitegromab.

Analysis

A recent shift in the competitive landscape materially increases the optionality of a single anti-myostatin program becoming the commercial reference in its indication set; that raises both peak pricing power and negotiating leverage with specialty pharmacies, but also concentrates downside risk into a single commercialization pathway. Expect payer dynamics to dominate realized revenue more than label breadth: if real-world functional gains are modest, PBMs and payers will push for step edits or significant rebates, compressing early launch revenue by 30–60% versus list-price models within the first 12–24 months.

Operationally, near-term execution risk centers on CMO scale-up and field reimbursement capability rather than further trial readouts — manufacturing setbacks or delayed distribution agreements could shave 20–40% off first-year uptake even with approval. Conversely, a clean regulatory outcome plus an aggressive specialty distribution roll-out can crystallize valuation uplifts quickly; anticipate 40–80% share moves on binary events over days around regulatory/label announcements.

The market reaction has likely priced a higher probability of market leadership; that is sensible only if commercial execution and payer access track expectations. The dominant contrarian risk is that class-level heterogeneity (variable patient response) translates into narrow labels and restricted coverage, a scenario underappreciated by momentum buyers that would drive a multi-quarter re-rating and leave funding optionality as the marginal constraint for continued operations.

Key Decisions for Investors

• Long SRRK equity (size: 1–2% NAV) on a 6–12 month horizon to play the pathway-to-market optionality; hedge with a 12-month SRRK 25–30% OTM put (costed) to cap asymmetric downside. Risk/Reward: downside limited to put cost + equity loss (capped ~30%), upside 50–80% on positive regulatory/commercial read-throughs.
• Event-driven options spread: buy SRRK 9–12 month call spread (buy near-ATM, sell ~40% OTM) to limit premium spend while capturing approval/label upside. Risk/Reward: limited max loss = net premium (~100% of premium), potential return 3–5x if catalyst prints favorably within term.
• Sell near-term volatility after initial pop: if shares gap >30% intraday post-news, initiate a covered-call overlay against new position (30–60 day calls) to monetize elevated IV and reduce carry; use proceeds to finance protective long-dated puts.
• Stop-loss and sizing guardrails: cap position to 2% NAV, hard stop at 35–45% drawdown if no near-term regulatory clarity within 6 months — preserves capital against class-level failures that historically produce multi-quarter de-ratings.